alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol
Resiquimod
CAS: 144875-48-9
Molecular Formula: C17H22N4O2
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Names and Identifiers
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Physico-chemical Properties
| Molecular Formula | C17H22N4O2 |
| Molar Mass | 314.382 |
| Density | 1.28 |
| Melting Point | 190-193° |
| Boling Point | 553.6±50.0 °C(Predicted) |
| Appearance | Shape powder, color white to tan |
| pKa | 14.63±0.29(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. |
| Physical and Chemical Properties | Bioactive Resiquimod (R-848, S28463) is an immune response modulator, which is used as an effective TLR 7/TLR 8 agonist and can induce up-regulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod can reduce hepatitis C virus (HCV) infection. Phase 2. |
| Use | Uses Reximod is used in scientific research reagents and is widely used in molecular biology, pharmacology and other scientific research. It is strictly prohibited to be used in human body. Resimod is an immune response modulator used as a potent TLR 7/8 agonist. |
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Risk and Safety
| WGK Germany | 3 |
| RTECS | NJ5911320 |
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.181 ml | 15.904 ml | 31.808 ml |
| 5 mM | 0.636 ml | 3.181 ml | 6.362 ml |
| 10 mM | 0.318 ml | 1.59 ml | 3.181 ml |
| 5 mM | 0.064 ml | 0.318 ml | 0.636 ml |
Last Update：2024-01-02 23:10:35
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Nature
| solubility | DMSO: soluble10mg/mL, clear (warmed to 60 °C) |
| maximum wavelength (& lambda;max) | 325nm(lit.) |
| Merck | 14,8151 |
Last Update：2024-04-10 22:41:03
alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol - Uses and synthesis methods
in vitro study
Resiquimod activates immune cells and induces proliferation of wild-type spleen cells through Toll-like receptor 7(TLR7)-MyD88-dependent signaling pathway. Resiquimod also regulate dendritic cells to increase cytomegalovirus-and HIV-1-specific T cell responses. Resiquimod induce myeloid-derived inhibitory cells to differentiate into macrophages and dendritic cells, and can improve the effect of cancer immunotherapy by reducing immunosuppressed MDSCs.
in vivo studies
In wild-type mice, Resiquimod (50 nmol, I. p.) induced an increase in serum concentrations of IFN-α,TNF-α, and IL-12, while mice with TLR7-deletion or MyD88-deletion did not increase their cytokines. In the mouse model of allergic asthma, Resiquimod (I. n., 20 μg/mouse) reduces allergen-induced airway response and inflammation by reducing Nrf2 signal.
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: RESIQUIMOD Visit Supplier Webpage Request for quotationCAS: 144875-48-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: RESIQUIMOD Visit Supplier Webpage Request for quotationCAS: 144875-48-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History